Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Lyric announces initial closing of $20.4 million Series A financing round

Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.

26 Feb 2015

UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

Margaret Riley, an evolutionary biologist at the University of Massachusetts Amherst and pioneer in fighting antibiotic-resistant bacteria, announced this week that she is partnering with a Chinese scientist to develop a new drug platform, pheromonicins. The Chinese government is committing $400 million per year to support the newly created Pheromonicin Institute of Beijing.

26 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Researchers introduce the idea of using sewage to study human microbiome

A new study demonstrates that sewage is an effective means to sample the fecal bacteria from millions of people. Researchers say the information gleaned from the work provides a unique opportunity to monitor, through gut microbes, the public health of a large population without compromising the privacy of individuals.

26 Feb 2015

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

RD Biomed to launch reflux diagnostic study in China

RD Biomed, the Hull-based medical technology company, will launch a study with over 1,000 patients in China to measure the effectiveness of its reflux diagnostic device Peptest.

24 Feb 2015

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function.

23 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Henry Ford researchers say that breastfeeding influences baby's immune system development

Henry Ford Hospital researchers say that breastfeeding and other factors influence a baby's immune system development and susceptibility to allergies and asthma by what's in their gut.

23 Feb 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse.

23 Feb 2015

Valeant Pharmaceuticals agrees to acquire Salix Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion.

23 Feb 2015

Actavis obtains final approval from FDA for generic Subutex

Actavis plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets).

21 Feb 2015

Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

In a new paper in the journal Infection and Immunity, the researchers lay out for the first time exactly how C. difficile wreaks havoc on the guts of animals in a short time, and causes severe diarrhea and life-threatening disease in humans.

19 Feb 2015

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis.

19 Feb 2015

Lupus Research Institute announces this year's Novel Research Grants

As the Lupus Research Institute celebrates its 15th anniversary, the engine of innovation moves forward at accelerated speed with the announcement of this year's Novel Research Grants bringing new talent from a wide diversity of specialties. Each project lives up to the strictest definition of novel – wholly original, never-been-done-before.

19 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

SLU researchers halt fatty liver disease in animal model

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences.

18 Feb 2015

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

Medics highlight underrepresentation of women in field

Hosted by the Sheffield Women in Medicine Network (SWiM), ‘Building Your Future - SWiM dives in with the Entrepreneurs’, will be a unique opportunity for women to hear personal stories from a diverse group of successful entrepreneurs and share experiences.

17 Feb 2015

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Lyric announces initial closing of $20.4 million Series A financing round

UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Researchers introduce the idea of using sewage to study human microbiome

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Actavis files ANDA to market Budesonide Extended-release Tablets

RD Biomed to launch reflux diagnostic study in China

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Henry Ford researchers say that breastfeeding influences baby's immune system development

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Valeant Pharmaceuticals agrees to acquire Salix Pharmaceuticals

Actavis obtains final approval from FDA for generic Subutex

Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

Possible cause of liver disease identified in adolescents with cystic fibrosis

Lupus Research Institute announces this year's Novel Research Grants

Actavis provides overview of standalone global pharmaceutical development pipeline

SLU researchers halt fatty liver disease in animal model

Second-line bosutinib well tolerated by Japanese patients

Medics highlight underrepresentation of women in field

Industry Focus eBook - Microbiology (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Industry Focus eBook - Microbiology (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in